Last reviewed · How we verify
NCT07077876: CHOICE
Surgical and Obstetric Outcomes in Endometrial Adenocarcinoma and Atypical Endometrial Hyperplasia With Conservative Treatment
trial testing Hysteroscopic Resection and Hormonal Therapy in Endometrial Adenocarcinoma in 100 participants. Currently enrolling.
30 June 2025
Quick facts
| Lead sponsor | Fondazione Policlinico Universitario Agostino Gemelli IRCCS |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 100 |
| Start date | 20 June 2025 |
| Primary completion | 30 June 2025 |
| Estimated completion | 20 January 2026 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- Hysteroscopic Resection and Hormonal Therapy
Conditions studied
- Endometrial Adenocarcinoma — all drugs for Endometrial Adenocarcinoma →
- Endometrial Hyperplasia — all drugs for Endometrial Hyperplasia →
- Fertility Preservation — all drugs for Fertility Preservation →
- Conservative Treatment Therapy — all drugs for Conservative Treatment Therapy →
Sponsor
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Who can join
18 and older, female only, with Endometrial Adenocarcinoma or Endometrial Hyperplasia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This observational study aims to evaluate the obstetric and oncological outcomes of patients diagnosed with endometrial adenocarcinoma (EAC) or atypical endometrial hyperplasia (AEH) who underwent conservative treatment at the CLASS Hysteroscopy Center of Fondazione Policlinico Universitario A. Gemelli IRCCS in Rome. Eligible patients include women who received hysteroscopic surgery and hormonal therapy either to preserve fertility or due to medical contraindications to standard radical surgery. Follow-up lasts 12 months.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Oncological and Reproductive Outcomes of a Standardized Hysteroscopic Approach for the Fertility-Sparing Treatment of Atypical Endometrial Hyperplasia and Early-Stage Endometrial Cancer
Catena U, Bonetti Palermo E, De Bonis F, Bruni G, et al · · 2026
Verify or expand the search:
- PubMed search for NCT07077876
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Endometrial Adenocarcinoma
Currently open trials in the same condition.
- NCT06917092 — QL1706-Based Therapy Post-PD-1/L1 Failure in Advanced Endometrial Cancer · Phase 2 · recruiting
- NCT05824481 — Study of Cadonilimab (AK104) Plus Lenvatinib in Patients With Advanced Endometrial Cancer · Phase 2 · active not recruiting
- NCT05548296 — A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma · Phase 2 · recruiting
- NCT05112601 — Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma · Phase 2 · recruiting
- NCT05655260 — PErsonalized TReatment for Endometrial Carcinoma · NA · recruiting
Other Fondazione Policlinico Universitario Agostino Gemelli IRCCS trials
Trials by the same sponsor.
- NCT07514572 — Impact of Estimated Weight and Height on Nutritional Assessment in Elderly · NA · not yet recruiting
- NCT07504679 — Adipose Visceral and Epicardial Risk Evaluation · NA · not yet recruiting
- NCT07520643 — MISTIC Study: Atherosclerosis, Neurocognition & Cardiovascular Signaling · not yet recruiting
- NCT07479238 — Breath Test-Based Assessment of SIBO in Chronic Pancreatitis and Partial Pancreatectomy · not yet recruiting
- NCT07494227 — Development of the SC-IBD Self-Care Measurement Scale · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07077876 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- Last refreshed: 22 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07077876.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing